

Valeriana Di Castro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3305071/publications.pdf>

Version: 2024-02-01

58
papers

3,165
citations

147566

31
h-index

189595

50
g-index

59
all docs

59
docs citations

59
times ranked

2961
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 157.	3.5	5
2	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. <i>Cancer Letters</i> , 2020, 492, 84-95.	3.2	12
3	Î2-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. <i>Nature Communications</i> , 2019, 10, 3196.	5.8	40
4	Blocking endothelin-1-receptor/Î2-catenin circuit sensitizes to chemotherapy in colorectal cancer. <i>Cell Death and Differentiation</i> , 2017, 24, 1811-1820.	5.0	34
5	Targeting endothelin-1 receptor/Î2-arrestin1 network for the treatment of ovarian cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 925-932.	1.5	9
6	Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. <i>Life Sciences</i> , 2016, 159, 43-48.	2.0	25
7	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. <i>Life Sciences</i> , 2016, 159, 49-54.	2.0	13
8	Endothelin A receptor drives invadopodia function and cell motility through the Î2-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. <i>Oncogene</i> , 2016, 35, 3432-3442.	2.6	53
9	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. <i>Oncotarget</i> , 2016, 7, 4009-4023.	0.8	49
10	Nuclear Î2-arrestin1 is a critical cofactor of hypoxia-inducible factor-1Î± signaling in endothelin-1-induced ovarian tumor progression. <i>Oncotarget</i> , 2016, 7, 17790-17804.	0.8	33
11	Abstract 2901: Nuclear Î2-arrestin1 is a critical cofactor of hypoxia-inducible factor-1Î± signaling in endothelin-1-induced ovarian tumor progression. , 2016, , .		0
12	Abstract 3580: Downregulated miR-30a promotes acquisition of chemoresistance by targeting endothelin A receptor in ovarian carcinoma. , 2015, , .		0
13	Endothelin A Receptor/Î2-Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy. <i>Cancer Research</i> , 2014, 74, 7453-7464.	0.4	89
14	Endothelin-1 regulates hypoxia-inducible factor-1Î± and -2Î± stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. <i>Life Sciences</i> , 2014, 118, 185-190.	2.0	19
15	The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. <i>Carcinogenesis</i> , 2014, 35, 840-848.	1.3	44
16	Î2-Arrestin 1 is required for endothelin-1-induced NF-Î²B activation in ovarian cancer cells. <i>Life Sciences</i> , 2014, 118, 179-184.	2.0	64
17	Abstract 3144: PDZ-RhoGEF/Î2-arrestin-1 interaction mediates endothelin A receptor-induced RhoA activation and cell motility in ovarian tumor cells. , 2014, , .		0
18	Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. <i>Journal of Molecular Medicine</i> , 2013, 91, 395-405.	1.7	48

#	ARTICLE	IF	CITATIONS
19	β -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β -catenin signaling. <i>Oncogene</i> , 2013, 32, 5066-5077.	2.6	79
20	The endothelin A receptor and epidermal growth factor receptor signaling converge on β -catenin to promote ovarian cancer metastasis. <i>Life Sciences</i> , 2012, 91, 550-556.	2.0	11
21	Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. <i>Life Sciences</i> , 2012, 91, 638-643.	2.0	15
22	Abstract 3086: β -arrestin-1 acts as a nuclear transcriptional regulator of endothelin A receptor signalling to promote ovarian cancer progression. , 2012, , .		0
23	Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 2350-2360.	3.2	167
24	Abstract 698: β -arrestin-1 as nuclear signalling element essential for endothelin A receptor-induced epithelial to mesenchymal transition and chemoresistance. , 2011, , .		0
25	Abstract 707: Acquisition of chemoresistance and epithelial to mesenchymal phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. , 2011, , .		0
26	317 Activation of the endothelin signaling pathway is linked with acquisition epithelial to mesenchymal transition phenotype of chemoresistant ovarian cancer cells. <i>European Journal of Cancer</i> , Supplement, 2010, 8, 101.	2.2	0
27	Combination therapy of zibotentan with cisplatin and paclitaxel is an effective regimen for epithelial ovarian cancer This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 676-681.	0.7	8
28	Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 782-787.	0.7	19
29	β -arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2010, 88, 796-801.	0.7	28
30	Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1 α in Melanoma Cells. <i>PLoS ONE</i> , 2010, 5, e11241.	1.1	50
31	β -Arrestin links endothelin A receptor to β -catenin signaling to induce ovarian cancer cell invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2806-2811.	3.3	159
32	Endothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade. <i>Cancer Research</i> , 2009, 69, 2669-2676.	0.4	87
33	168 POSTER Endothelin A receptor/beta-arrestin signaling is critical for ovarian cancer metastasis: novel molecular therapeutic applications. <i>European Journal of Cancer</i> , Supplement, 2008, 6, 54.	2.2	0
34	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. <i>Cancer Research</i> , 2007, 67, 6351-6359.	0.4	65
35	Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1 α in Human Melanoma Cells. <i>Cancer Research</i> , 2007, 67, 1725-1734.	0.4	84
36	ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2003-2011.	1.9	61

#	ARTICLE	IF	CITATIONS
37	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1483-1492.	1.9	73
38	Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 833-842.	1.9	74
39	Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells. <i>Cancer Research</i> , 2005, 65, 11649-11657.	0.4	161
40	Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression. <i>Cancer Research</i> , 2004, 64, 1436-1443.	0.4	115
41	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4670-4679.	3.2	62
42	Therapeutic Targeting of the Endothelin-A Receptor in Human Ovarian Carcinoma: Efficacy of Cytotoxic Agents is Markedly Enhanced by Co-administration with Atrasentan. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S132-S135.	0.8	7
43	Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion. <i>Journal of Biological Chemistry</i> , 2004, 279, 46700-46705.	1.6	91
44	Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S140-S143.	0.8	20
45	Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S136-S139.	0.8	12
46	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. <i>American Journal of Pathology</i> , 2003, 163, 753-762.	1.9	55
47	Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 41294-41301.	1.6	64
48	Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. <i>Cancer Research</i> , 2003, 63, 2447-53.	0.4	90
49	Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1 α in Ovarian Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 27850-27855.	1.6	182
50	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. <i>Molecular Pharmacology</i> , 2002, 61, 524-532.	1.0	132
51	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. <i>Clinical Science</i> , 2002, 103, 302S-305S.	1.8	24
52	Endothelin-1 promotes proteolytic activity of ovarian carcinoma. <i>Clinical Science</i> , 2002, 103, 306S-309S.	1.8	31
53	ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth <i>in vitro</i> . <i>Clinical Science</i> , 2002, 103, 318S-321S.	1.8	21
54	Endothelin Receptor Blockade Inhibits Proliferation of Kaposi's Sarcoma Cells. <i>American Journal of Pathology</i> , 2001, 158, 841-847.	1.9	34

#	ARTICLE	IF	CITATIONS
55	Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma. American Journal of Pathology, 2000, 157, 1537-1547.	1.9	184
56	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	1.9	322
57	The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop. Journal of Virology, 1997, 71, 6898-6904.	1.5	12
58	Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human Keratinocytes. Biochemical and Biophysical Research Communications, 1995, 209, 80-86.	1.0	29